

Amendment to the Claims:

Please amend the claims as follows.

This listing of claims will replace all prior versions, and listing, of claims in the application:

Listing of Claims:

Claim 1 (previously presented): A method for treating myeloma, comprising:

(A) (a) providing an anti-IL-6 receptor antibody that inhibits signal transmission of IL-6 by blocking the binding of IL-6 ligand to IL-6 receptor;

(b) providing a nitrogen mustard anticancer agent; and

(c) administering the nitrogen mustard anticancer agent in combination with the anti-IL-6 receptor antibody as part of a treatment regimen,

wherein the co-administration of nitrogen mustard anticancer agent and the anti-IL-6 receptor antibody has a higher (synergistic) therapeutic effect for myeloma than when the anti-IL-6 receptor antibody alone is administered or when the nitrogen mustard anticancer agent alone is administered; or

(B) the method of (A), wherein the anti-IL-6 receptor antibody and the nitrogen mustard anticancer agent are formulated in separate pharmaceutical compositions which are administered at different times or are administered at the same time, or the anti-IL-6 receptor antibody and the nitrogen mustard anticancer agent are formulated in one pharmaceutical composition.

Claim 2 (previously presented): The method according to claim 1, wherein the anti-IL-6 receptor antibody comprises a monoclonal antibody.

Claim 3 (previously presented): The method according to claim 2, wherein the monoclonal antibody comprises a PM-1 antibody deposited as FERM BP-2998.

Claim 4 (previously presented): The method according to claim 3, wherein the PM-1 antibody comprises a reshaped human PM-1 antibody.

Claim 5 (previously presented): The method according to claim 1, wherein the nitrogen mustard anticancer agent comprises mechlorethamine, nitrogen mustard N-oxide, melphalan, uramustin, ifosfamide, chlorambucil, or cyclophosphamide, or a combination thereof.

Claim 6 (previously presented): The method according to claim 1, wherein (a) the nitrogen mustard anticancer agent is melphalan; or, (b) the method of (a), wherein the melphalan is administered as an oral administration of 1 to 20 mg per day, every day or 1 to 6 times per week, or as high-dose intravenous injection or infusion, single or multiple doses of 20 to 200 mg/m<sup>2</sup>.

Claim 7 (previously presented): A method for treating myeloma, comprising  
(A) administering an anti-IL-6 receptor antibody in combination with a nitrogen mustard anticancer agent as part of a treatment regimen,  
wherein the anti-IL-6 receptor antibody or the nitrogen mustard anticancer agent is administered in an amount to have a higher (synergistic) therapeutic effect for myeloma than when the nitrogen mustard anticancer agent is administered alone, or when the anti-IL-6 receptor antibody is administered alone; or  
(B) the method of (A), wherein the anti-IL-6 receptor antibody and the nitrogen mustard anticancer agent are formulated in separate pharmaceutical compositions which are administered at different times or are administered at the same time, or the anti-IL-6 receptor antibody and the nitrogen mustard anticancer agent are formulated in one pharmaceutical composition.

Claim 8 (previously presented): The method according to claim 7, wherein the anti-IL-6 receptor antibody comprises a monoclonal antibody.

Claim 9 (previously presented): The method according to claim 8, wherein the monoclonal antibody comprises a PM-1 antibody deposited as FERM BP-2998.

Claim 10 (previously presented): The method according to claim 9, wherein the PM-1 antibody comprises a reshaped human PM-1 antibody.

Claim 11 (previously presented): The method according to claim 7, wherein the nitrogen mustard anticancer agent comprises mechlorethamine, nitrogen mustard N-oxide, melphalan, uramustin, ifosfamide, chlorambucil, or cyclophosphamide, or a combination thereof.

Claim 12 (previously presented): The method according to claim 7, wherein the nitrogen mustard anticancer agent comprises melphalan.

Claim 13 (previously presented): The method of claim 12, wherein the melphalan is administered as an oral administration of 1 to 20 mg per day, every day or 1 to 6 times per week, or as high-dose intravenous injection or infusion, single or multiple doses of 20 to 200 mg/m<sup>2</sup>.

Claim 14 (currently amended): The method of claim 12, wherein the **[[a]]** pharmaceutical composition comprising a nitrogen mustard anticancer agent is administered simultaneously with the anti-IL-6 receptor antibody, and the ratio, is, when combined with daily oral administration of melphalan, 0.01 to 1000 fold (weight ratio) relative to the dose of melphalan.

Claim 15 (currently amended): The method of claim 1, wherein the **[[a]]** pharmaceutical composition comprising a nitrogen mustard anticancer agent is administered orally, by intravenous injection, drip infusion, intraarterial injection, intramuscular injection, intratumor injection, intrathoracic injection, or intraperitoneal injection, either systemically or locally.

Claim 16 (currently amended): The method of claim 1, wherein the **[[a]]** pharmaceutical composition comprising anti-IL-6 receptor antibody is administered parenterally, by intravenous injection, drip infusion, intramuscular injection, intraperitoneal injection, subcutaneous injection, either systemically or locally; or, is administered as local dosage-forms, external preparations, local injections; or, as external preparations, liniments, ointments, gel, cream, emulsions, and liquids, tapes, plaster tapes, patches, nebulas, sprays or powders.

Claim 17 (previously presented): A method for treating a myeloma comprising:

(A) (a) providing at least one pharmaceutical composition comprising separately or in combination:

(i) an anti-IL-6 receptor antibody that inhibits signal transmission of IL-6 by blocking the binding of IL-6 ligand to IL-6 receptor, and

(ii) a nitrogen mustard anticancer agent comprising melphalan; and

(b) administering to an individual in need thereof the pharmaceutical composition as part of a treatment regimen,

wherein the co-administration of nitrogen mustard anticancer agent and the anti-IL-6 receptor antibody has a higher (synergistic) therapeutic effect for myeloma than when the anti-IL-6 receptor antibody alone is administered or when the nitrogen mustard anticancer agent alone is administered; or

(B) the method of (A), wherein the anti-IL-6 receptor antibody and the nitrogen mustard anticancer agent are formulated in separate pharmaceutical compositions which are administered at different times or are administered at the same time, or the anti-IL-6 receptor antibody and the nitrogen mustard anticancer agent are formulated in one pharmaceutical composition.

Claim 18 (previously presented): The method of claim 1, wherein treating myeloma comprises a life elongation effect.

Claim 19 (previously presented): The method of claim 7, wherein treating myeloma comprises a life elongation effect.

Claim 20 (previously presented): The method of claim 17, wherein treating myeloma comprises a life elongation effect.